Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Tryptamine Therapeutics ( (AU:TYP) ) has shared an announcement.
Tryptamine Therapeutics Limited has appointed BDO Audit Pty Ltd as its new auditor, replacing William Buck Audit (VIC) Pty Ltd, effective January 6, 2025. This change aligns with the company’s status as a designated foreign issuer in Canada, requiring an auditor registered with the Canadian Accounting Board. The board’s decision reflects BDO’s global reach and expertise, aiming to enhance compliance and operational efficiency. The appointment will be ratified at the next Annual General Meeting, signaling a strategic move for Tryptamine in maintaining its regulatory obligations and potentially strengthening its market position.
More about Tryptamine Therapeutics
Tryptamine Therapeutics Limited, a clinical-stage biopharmaceutical company, focuses on developing proprietary formulations of psilocin combined with psychotherapy to treat diseases with unmet medical needs. Its lead asset, TRP-8803, is an IV-infused formulation of psilocin designed to improve the efficacy and duration of psychedelic therapy. The company has conducted successful clinical trials for conditions like binge eating disorder and fibromyalgia, and is exploring treatments for irritable bowel syndrome.
YTD Price Performance: 5.00%
Average Trading Volume: 3,943,725
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$53.61M
See more data about TYP stock on TipRanks’ Stock Analysis page.
Trending Articles
- Top Analyst Bangs the Drum on MicroStrategy Stock
- ‘Too Cheap to Ignore,’ Says Investor About AMD Stock
- ‘Hold Off,’ Say Analysts About Rivian Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
